Avanir Pharmaceuticals (AVNR) Reports Significant Data from AVP-923 Phase 2
Tweet Send to a Friend
Avanir Pharmaceuticals (Nasdaq: AVNR) announced positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
